- Home
- ABOS vs BEAT Comparison
ABOS vs BEAT Comparison
Compare ABOS & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- BEAT
- Stock Information
- Founded
- ABOS 1996
- BEAT 2015
- Country
- ABOS United States
- BEAT United States
- Employees
- ABOS N/A
- BEAT N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ABOS Health Care
- BEAT Technology
- Exchange
- ABOS Nasdaq
- BEAT Nasdaq
- Market Cap
- ABOS 66.6M
- BEAT 59.0M
- IPO Year
- ABOS 2021
- BEAT 2021
- Fundamental
- Price
- ABOS $0.98
- BEAT $1.60
- Analyst Decision
- ABOS Strong Buy
- BEAT Buy
- Analyst Count
- ABOS 3
- BEAT 1
- Target Price
- ABOS $7.33
- BEAT $8.00
- AVG Volume (30 Days)
- ABOS 215.0K
- BEAT 60.4K
- Earning Date
- ABOS 05-13-2025
- BEAT 05-13-2025
- Dividend Yield
- ABOS N/A
- BEAT N/A
- EPS Growth
- ABOS N/A
- BEAT N/A
- EPS
- ABOS N/A
- BEAT N/A
- Revenue
- ABOS N/A
- BEAT N/A
- Revenue This Year
- ABOS N/A
- BEAT N/A
- Revenue Next Year
- ABOS N/A
- BEAT N/A
- P/E Ratio
- ABOS N/A
- BEAT N/A
- Revenue Growth
- ABOS N/A
- BEAT N/A
- 52 Week Low
- ABOS $0.86
- BEAT $1.45
- 52 Week High
- ABOS $3.92
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ABOS 43.50
- BEAT 37.57
- Support Level
- ABOS $0.96
- BEAT $1.78
- Resistance Level
- ABOS $1.13
- BEAT $1.91
- Average True Range (ATR)
- ABOS 0.08
- BEAT 0.14
- MACD
- ABOS 0.00
- BEAT -0.01
- Stochastic Oscillator
- ABOS 10.71
- BEAT 6.31
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.